



Optimising the management of DME: Improving patient outcomes



Chair:
Tien Yin Wong,
Singapore

We welcome you to engage with our panel of leading experts as they share the latest evidence-based guidance on DME management to ensure optimal treatment outcomes with aflibercept for your patients.

Sunday, December 12, 2021 | 12:00–13:00 (SGT; GMT+8)



Michael Stewart,
USA



Neil Bressler*,
USA



Voraporn
Chaikitmongkol,
Thailand



**For more information or to add the symposium to your calendar,
click or scan the QR code!**

*Participation by Dr N. Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital or the Johns Hopkins Health System, nor by the DRCR retina Network or *JAMA Ophthalmology*. APVRS, Asia-Pacific Vitreo-Retina Society; DME, diabetic macular edema; DRCR, Diabetic Retinopathy Clinical Research.
This symposium is organised and funded by Bayer.

For further information on aflibercept solution for injection, please consult your local prescribing information.

Bayer (South East Asia) Pte Ltd.
2, Tanjong Katong Road #07-01, Paya Lebar
Quarter 3, Singapore 437161.
Tel: +65 6496 1888 | Fax: +65 6496 1491



Achieving benefits for patients through proactive, individualised T&E in nAMD and PCV



Chair:
Andrew Chang,
Australia

Join our expert panel for guidance on proactive T&E regimens with aflibercept, including flexible retreatment criteria enabling individualisation from q4–q16, to cater for the diverse needs of your patients.

Saturday, December 11, 2021 | 18:15–19:15 (SGT; GMT+8)



Nancy Holekamp,
USA



Diana Do,
USA



Anna Tan,
Singapore



For more information or to add the symposium to your calendar, click or scan the QR code!

APVRS, Asia-Pacific Vitreo-retina Society; nAMD, neovascular age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; q4, every 4 weeks; q16, every 16 weeks; T&E, treat-and-extend.

This symposium is organised and funded by Bayer.

For further information on aflibercept solution for injection, please consult your local prescribing information.

Bayer (South East Asia) Pte Ltd.
2, Tanjong Katong Road #07-01, Paya Lebar Quarter 3, Singapore 437161.
Tel: +65 6496 1888 | Fax: +65 6496 1491

The Vision Academy – providing a sharper focus on the future of patient care in retinal disease



The Vision Academy is a group of over 100 international ophthalmology experts, working together to identify and address clinical challenges in retinal disease by providing expert guidance for best clinical practice, especially in areas with insufficient conclusive evidence.

CLINICAL CHALLENGES BEING ADDRESSED BY THE VISION ACADEMY

Available Materials

- Use of topical antibiotics with intravitreal injections (updated)
- Fundamental principles of an anti-VEGF treatment regimen
- Additional measures of visual function beyond acuity
- The role of OCT-A in retinal disease management
- Bilateral anti-VEGF treatment (updated)
- Management of subfoveal hemorrhage
- Management of RPE tear
- Coordinated care in diabetic eye disease management
- Suspending treatment of nAMD in cases of futility
- Pachychoroid – definition and pathogenesis
- Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
- Principles of a DR screening program
- Monitoring of the fellow eye in nAMD
- RWE: conducting an audit
- Insights gained from RWE
- Novel tool to assess the quality of RWE to guide management of retinal disease
- Navigating RWE in ophthalmology



Coming Soon

- Vision-related QoL in retinal disease
- Characterization of AMD subtypes
- Role of residual fluid in nAMD
- Impact of anti-VEGF therapy on IOP and optic nerve
- Simplified recommendations for management of DME
- Fundamental principles of an anti-VEGF treatment regimen (update)
- Management of CSCR
- Cataract surgery and anti-VEGF management
- Management of non-exudative SRNV
- Suspending anti-VEGF treatment in cases of success
- Biomarkers of disease activity: AMD
- Biomarkers of disease activity: DME
- AI in retinal diseases
- Regression in diabetic retinopathy severity score with anti-VEGF treatment
- The course of retinal ischemia during anti-VEGF therapy of DR



- How to manage early AMD
- Epiretinal membrane and vitreomacular traction in DME and RVO
- Simultaneous GA and CNV/MNV
- Development and standardization of “time in range” measurement